Leading the Way in Life Science Technologies

GEN Exclusives

More »


More »
November 01, 2010 (Vol. 30, No. 19)

Biotech Posts Strong Third-Quarter Results

Robust Performance Hailed as Strongest September Rally in More than 70 Years

  • Partnering Continues to Be Hot

    Of the partnership deals that disclosed their financial terms, a whopping $9.6 billion was collectively raised in the third quarter of 2010 by U.S. biotech companies—up 8% on the $8.9 billion raised through partnership deals in Q2’10.

    We are on pace to equal last year’s record-setting total for partnership dollars, an incredible amount given the uncertain economic environment and testimony that pharma’s appetite for biotech innovation continues unabated.

    We did predict at the beginning of the year that the general markets would be choppy and that biotech companies would begin to perform well in the second half of the year. It appears that this scenario is beginning to play out as we enter the final quarter of the year.

    Although all the biotech companies that have completed their IPOs this year have  not performed well so far, we believe there will be at least another five getting out before the end of the year. Investor interest will be fueled by two high-profile genomics companies—Complete Genomics and Pacific Biosciences—and the traditional bullish trend for biotech in the fourth quarter.

  • By the Numbers

    1 The industry closed the third quarter with a collective market cap of $350.48 billion (up 9.8% for the month, up 6.8% for the quarter, and up 0.4% for the year).

    2 Fifty-five biotech companies (18%) have market caps greater than $1 billion, compared to 49 companies at the same time last year.

    3 Ninety-eight biotech companies (32%) have market caps less than $100 million, compared to 39%
    (122 companies) at the same time last year.

Related content